Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Proving Medical Necessity: HHS “Essential Benefits” Standards In The Works

Executive Summary

The Institute of Medicine is seeking public comment on criteria and methods for determining and updating what qualify as essential health benefits for insurance plans that will become available in state-operated exchanges in 2014.

You may also be interested in...



Drug Coverage In Exchange Plans Should Be On Par With Other "Essential Benefits," PhRMA Tells IoM

PhRMA was among a number of stakeholders presenting comments Jan. 14 to the committee on criteria and methods for determining and updating what qualifies as "essential health benefits" in the exchange plans.

Xtandi Pricing and Patents: Alternatives To March-In Urged To Lower Medicare, Medicaid Costs

The timing of the request, with Xtandi’s loss of exclusivity on the horizon, could be explained by the concern that a change in the US presidential administration in 2025 may limit the prospects for near-term relief.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS052889

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel